linagliptin manufacturer Supply linagliptin api CAS NO.668270-12-0

What's the Linagliptin

Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for treatment of type II diabetes.
Linagliptin was approved by the U.S. Food and Drug Administration (FDA) on 2 May 2011 for treatment of type II diabetes.

Function:

1. Incretin (Incretin) has the role of intestinal promoting insulin B cells to secrete insulin, mainly including glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). DDP-4 is a serine protease located on the cell surface, which is widely found in plasma and in vivo tissues (such as kidney, liver, small intestine villi, endothelial cells, etc.). Rilalitine is a selective DPP-4 inhibitor that inhibits the activity of the enzyme by reversibly binding to DPP-4, delays GLP-1 degradation, enhances GLP-1 activity, and stimulates glucose-dependent Insulin secretion, and reduce circulating levels of glucagon, thereby regulating blood glucose levels in patients with type 2 diabetes.

2. Compared with other DPP-4 inhibitors, the main advantages of liradetine is: with excellent renal safety, and can effectively reduce glycosylated hemoglobin. Lilardine mainly in the form of excretion of fecal excretion, the oral administration, the amount of renal excretion is only 5% of the dose, even if the intravenous administration, and only 30.8% of the excretion by the kidney, so the patient did not need treatment Regularly check the liver, kidney function and dose adjustment, all patients can be a unified fixed dose, easy to prescribe.